Download Personal genomics

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Maryam Nazir
Personal Genomics:
Branch of genomics
concerned with the
sequencing and analysis of
the genome of an individual
 Once sequenced, it can be
compared with published
literature to determine
likelihood of disease risk or
trait expression
 Main aim: to inform
preventative action

Techniques
SNP arrays
 Partial sequencing
 Whole genome sequencing

 Can be used to evaluate:
○ SNPs
○ Indels
○ Large SVs
○ New sequences
○ Haplotypes
Cost of Sequencing

Continual development of new sequencing
technologies, next-generation sequencing
 Increased speed
and reduced cost
of sequencing
 Now possible to
offer genetic
testing to
consumers
Personal Genome Project
Large, long-term study
 Aim: To sequence and publicize the
complete genomes and medical records
of 100,000 volunteers
 All data will be available in the public
domain
 Purpose: To enable research in personal
genomics and personalized medicine


Each participant:
 Full DNA sequence
 Extensive phenotype information
○ Medical records
○ MRI images
○ Other measurements

Volunteer criteria:




Permanent residents of the US, Canada, UK
Able to submit tissue and/or genetic samples
Informed consent
“no promise of anonymity and data return”
Personalized Medicine



A model of medicine which
proposes the customization of
healthcare with medical decisions
being tailored to the individual
patient
Goal: To individualize prevention,
diagnosis, and treatment--by use of
genetic differences as markers
Disease risk
 >2500 diseases have predictive
medical value
○ Can be recommended for genetic tests
for single genes or whole genome
sequencing

Gene signatures
 Gene expression pattern in a cell can be uniquely
characteristic of a condition
 Risk assessment, diagnostic & prognostic applications
 Match patients and treatments
Pharmacogenomics
Field that analyzes how
genetic makeup affects an
individual’s response to
drugs
 Want to tailor treatments for
patients based on their
genetics

Cancer genomics
Main goal: to identify genes, or gene
signatures, that may provide insights into
cancer diagnosis, predicting clinical
outcomes or targets for cancer therapies
 Tumour sequence is compared to a
matched normal tissue
 Personalized cancer treatments
 Genetic profiles of tumours part of
recommended evaluation for certain
cancers (colon, breast, lung...)

Nutrigenomics
Study of how individual
genetic variation affects a
person’s response to
nutrients and impacts their
risk of nutrition-related
chronic diseases
 People respond differently to
certain foods

Human Ancestry
Looks at a person’s DNA at
specific locations compares
results to defined groups
 Mitochondrial DNA

 Traces direct maternal line

Y-Chromosome DNA
 Traces a male’s direct paternal
line

Autosomal DNA
 Tests all ancestry, shows how
closely a person is related to
others
Commercial Services

Gentle
 most comprehensive genetic test currently
on the market
 screens for >1700 genetic conditions
 predicts response to certain medications

HelloGenome (Korea)
 genotyping (SNP chips) and full genome sequencing
(Solexa machines)

Illumina, Sequenom, Oxford Nanopore
Technologies, Pacific Biosciences, Complete
Genomics, 454 Life Sciences
 commercializing full genome sequencing
 do not provide any genetic analysis or counselling
component

Positive Bioscience
(Mumbai)
 Next-generation sequencing
 To determine most beneficial
cancer treatment for patients

Nutrigenomix
 SNP genotyping
 Each gene tested is involved in
the way the body processes a
certain dietary component
 With information obtained, can
tailor the diet to prevent
chronic diseases (cancer, heart
disease, type 2 diabetes)
-ex. Caffeine
 Only available through
registered dieticians
 $385
23andMe
Mail order “spit kits”
 SNP genotyping (DNA array)
 Assessment of:

 inherited traits
 ancestry
 genetic risk for >240 diseases and common
conditions
Information presented in user profile
 $99

Ethical Issues

Personal privacy & misuse of information
 Whose responsibility?
 Who owns the genomic info?

Genetic discrimination
 Discrimination based on information obtained
from an individual’s genome
 Genetic Information Nondiscrimination Act
(U.S.)
○ Prevents discrimination by health insurers and
employers, but does not apply to life insurance
or long-term care insurance

Psychosocial stress
 Consequence of knowing one’s predisposition
to disease
 Know risk, have no cure
Other Issues
How relevant are the
results of commercial
services? Clinical utility?
 Education needed in
interpreting results and
communicating genetic
information

 For the average
person/patient
 For doctors
 For the public & media
 genetic counselling
Conclusions

A fairly large number of loci that are known to
be predictive of disease have been identified
 Many of these can be clinically targeted
Immediate applications are limited at present
 The promise of personal genomics lies in the
future

 Must first build a database of personal genomes

Many people envision a future where personal
genomic information is one of the essential
tools used to tailor one’s medical care
References

Offit, Kenneth. "Personalized medicine: new genomics, old
lessons." Hum Genet. 130. (2011): 3-14.

Snyder, Michael, Jiang Du, and Mark Gerstein. "Personal
genome sequencing: current approaches and
challenges." Genes Dev. 24. (2010): 423-431.

Werner, Thomas. "Next generation sequencing in functional
genomics." Briefings in Bioinformatics. 2.5 (2010): 499-511.

Cooper, David N., et al. "Genes, Mutations, and Human
Inherited Disease at the Dawn of the Age of Personalized
Genomics." Human Mutation. 31.6 (2010): 631–655.

Chin, Lynda, Jannick N Andersen1, and P Andrew Futreal.
"Cancer genomics: from discovery science to personalized
medicine." Nature Medicine. 17.3 (2011): 297-303.